With a net loss of $2.9 million (5 cents/share) for the quarter ending March 31, Cellectar Biosciences improved its financial picture compared to the same period a year ago when it reported a net loss of $3.5 million (7 cents/share). The Madison biopharmaceutical company is developing drugs to fight against cancer and is also working on a product to image a type of brain cancer.
Cellectar narrows its losses
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
